Watchlistverdächtig!Genetic Immunity, InPlay - 500 Beiträge pro Seite
eröffnet am 16.04.09 19:40:40 von
neuester Beitrag 01.07.09 17:03:03 von
neuester Beitrag 01.07.09 17:03:03 von
Beiträge: 12
ID: 1.149.733
ID: 1.149.733
Aufrufe heute: 0
Gesamt: 2.081
Gesamt: 2.081
Aktive User: 0
ISIN: US7393061087 · WKN: A0RMTU
0,0084
USD
+15,38 %
+0,0011 USD
Letzter Kurs 22.09.17 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Dienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7000 | +75,00 | |
| 6,2500 | +35,87 | |
| 3,0200 | +25,83 | |
| 0,6500 | +21,50 | |
| 2,5000 | +19,05 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0100 | -18,55 | |
| 19,010 | -23,96 | |
| 0,6300 | -30,00 | |
| 1,1100 | -63,61 | |
| 8,2100 | -89,71 |
Feedback
Kein Thread vorhanden!
Hier die letzte news !
Beobachten?
Genetic Immunity, InPlay: Second Phase II Clinical Trial Commences in Italy on Company's Lead Product Candidate DermaVir Patch HIV Vaccine
* Thursday April 16, 2009, 9:52 am EDT
*
Buzz up!
* Print
BUDAPEST, HUNGARY--(MARKET WIRE)--Apr 16, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce the commencement of an exploratory Phase II clinical trial of the Company's DermaVir Patch HIV nanomedicine vaccine lead product candidate being conducted at Policlinico San Matteo in Pavia, Italy.
This Phase II, randomized, placebo-controlled trial is designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific memory T cells in HIV-1-infected individuals, and whether the quantity of these memory T cells correlate with the viral load set point following analytical treatment interruption (ATI). Subjects are being randomized to receive either DermaVir Patch (8 subjects per cohort) or Placebo Patch (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks. The trial will employ a novel assay of memory T-cell function known as the PHPC (Precursors with High Proliferative Capacity) assay developed by ViroStatics, srl, the Italian partner of Genetic Immunity.
"I look forward to obtaining results from this, our second in-progress Phase II trial for DermaVir. I believe results will be outstanding and closely correlate with those of our first Phase II trial underway in Germany and allow us to quickly move forward to Phase III in the not too distant future. When successful, DermaVir can become the first effective HIV immune-based treatment on the market within the next few years," commented Julianna Lisziewicz, CEO of Genetic Immunity.
"The trial has the potential to indicate biomarkers of immune control of HIV. We are very glad we can test the hypothesis by employing DermaVir, one of the best immune-based product candidates available," added Franco Lori, Protocol Chair of the Trial.
A total of 16 subjects will be enrolled and randomized to receive DermaVir Patch (8 subjects) or DermaVir Patch Placebo (8 subjects). As of the date of this press release three patients have already been enrolled.
For more information please visit the Company's official website at http://www.geneticimmunity.com or contact Zsolt Lisziewicz directly at +36-1-272-0364.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Hier die letzte news !
Beobachten?
Genetic Immunity, InPlay: Second Phase II Clinical Trial Commences in Italy on Company's Lead Product Candidate DermaVir Patch HIV Vaccine
* Thursday April 16, 2009, 9:52 am EDT
*
Buzz up!
BUDAPEST, HUNGARY--(MARKET WIRE)--Apr 16, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce the commencement of an exploratory Phase II clinical trial of the Company's DermaVir Patch HIV nanomedicine vaccine lead product candidate being conducted at Policlinico San Matteo in Pavia, Italy.
This Phase II, randomized, placebo-controlled trial is designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific memory T cells in HIV-1-infected individuals, and whether the quantity of these memory T cells correlate with the viral load set point following analytical treatment interruption (ATI). Subjects are being randomized to receive either DermaVir Patch (8 subjects per cohort) or Placebo Patch (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks. The trial will employ a novel assay of memory T-cell function known as the PHPC (Precursors with High Proliferative Capacity) assay developed by ViroStatics, srl, the Italian partner of Genetic Immunity.
"I look forward to obtaining results from this, our second in-progress Phase II trial for DermaVir. I believe results will be outstanding and closely correlate with those of our first Phase II trial underway in Germany and allow us to quickly move forward to Phase III in the not too distant future. When successful, DermaVir can become the first effective HIV immune-based treatment on the market within the next few years," commented Julianna Lisziewicz, CEO of Genetic Immunity.
"The trial has the potential to indicate biomarkers of immune control of HIV. We are very glad we can test the hypothesis by employing DermaVir, one of the best immune-based product candidates available," added Franco Lori, Protocol Chair of the Trial.
A total of 16 subjects will be enrolled and randomized to receive DermaVir Patch (8 subjects) or DermaVir Patch Placebo (8 subjects). As of the date of this press release three patients have already been enrolled.
For more information please visit the Company's official website at http://www.geneticimmunity.com or contact Zsolt Lisziewicz directly at +36-1-272-0364.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
enetic Immunity, InPlay: Genetic Immunity Licenses Plasmid DNA Purification Technology
* Wednesday April 1, 2009, 9:51 am EDT
*
Buzz up!
* Print
BUDAPEST, HUNGARY--(MARKET WIRE)--Apr 1, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce the licensing of a large-scale purification process for pharmaceutical grade plasmid-DNA manufacturing from Aldevron LLC, a US based contract manufacturing organization that specializes in purifying plasmid-DNA and other biological molecules.
"We have been working with the Aldevron team for a year now to develop technology suitable for manufacturing large plasmid DNA ( > 10kb). One of the limitations we encountered in trying to use current DNA manufacturing technologies was that current suppliers have optimized their technology for much smaller plasmid DNA manufacturing. These processes are not suitable for manufacturing the required quantity and quality of large plasmid DNAs we need. The Active Pharmaceutical Ingredients in our products are large plasmid DNAs expressing simultaneously many antigens. For example, the DNA in our DermaVir Patch investigational HIV vaccine is almost 12kB. It has been very challenging to obtain from contract manufacturers acceptable quantity and quality of this size plasmid DNA," commented Julianna Lisziewicz, CEO of the Company.
"We are very excited to be working with Genetic Immunity and helping them meet their quality and production requirements in support of phase II clinical trials and beyond. We view all of our work with clients as collaborative efforts and this collaboration with Genetic Immunity has resulted in several interesting manufacturing innovations," added Justin Poley, Business Development Director Aldevron LLC.
"We are very happy to have acquired a license to this technology from Aldevron because it is optimized to our plasmid DNA needs. Of equal importance is the fact that the quality of the DNA produced is suitable for our patented nanoformulation technology. Once our manufacturing facilities are established in Budapest we plan on becoming the largest producer of plasmid-DNA in Central-Eastern Europe. This will not only allow us to meet our own needs, but to supply the best quality products to other companies and researchers working in this field. Our facility will also allow us to meet stringent quality control and volume needs as we move forward with several clinical trials, and the eventual treatment of patients. Genetic immunity is not just a cutting edge Research and Development Company, our vision is to produce the products needed for our protocols and treatments," commented Zsolt Lisziewicz, COO of the Company.
Plasmids are closed circular molecules of double-stranded DNA that range in size from 1 to > 20 kB. Plasmids often contain genes that code for antigens and enzymes that can be advantageous to the host cell in some circumstances. The encoded proteins may be involved in inducing immune responses, resistance to, or production of antibiotics, resistance to toxins. Genetic Immunity proprietary DermaVir Patch technology uses special, 12kB plasmid-DNA, encoding most of the HIV genetic information. The plasmid is formulated to a nanomedicine and delivered to the dendritic cells of the lymph nodes to induce potent immune responses.
For more information please visit the Company's official website at http://www.geneticimmunity.com or contact Zsolt Lisziewicz directly at +36-1-272-0364
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Contact:
Contact:
At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
* Wednesday April 1, 2009, 9:51 am EDT
*
Buzz up!
BUDAPEST, HUNGARY--(MARKET WIRE)--Apr 1, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce the licensing of a large-scale purification process for pharmaceutical grade plasmid-DNA manufacturing from Aldevron LLC, a US based contract manufacturing organization that specializes in purifying plasmid-DNA and other biological molecules.
"We have been working with the Aldevron team for a year now to develop technology suitable for manufacturing large plasmid DNA ( > 10kb). One of the limitations we encountered in trying to use current DNA manufacturing technologies was that current suppliers have optimized their technology for much smaller plasmid DNA manufacturing. These processes are not suitable for manufacturing the required quantity and quality of large plasmid DNAs we need. The Active Pharmaceutical Ingredients in our products are large plasmid DNAs expressing simultaneously many antigens. For example, the DNA in our DermaVir Patch investigational HIV vaccine is almost 12kB. It has been very challenging to obtain from contract manufacturers acceptable quantity and quality of this size plasmid DNA," commented Julianna Lisziewicz, CEO of the Company.
"We are very excited to be working with Genetic Immunity and helping them meet their quality and production requirements in support of phase II clinical trials and beyond. We view all of our work with clients as collaborative efforts and this collaboration with Genetic Immunity has resulted in several interesting manufacturing innovations," added Justin Poley, Business Development Director Aldevron LLC.
"We are very happy to have acquired a license to this technology from Aldevron because it is optimized to our plasmid DNA needs. Of equal importance is the fact that the quality of the DNA produced is suitable for our patented nanoformulation technology. Once our manufacturing facilities are established in Budapest we plan on becoming the largest producer of plasmid-DNA in Central-Eastern Europe. This will not only allow us to meet our own needs, but to supply the best quality products to other companies and researchers working in this field. Our facility will also allow us to meet stringent quality control and volume needs as we move forward with several clinical trials, and the eventual treatment of patients. Genetic immunity is not just a cutting edge Research and Development Company, our vision is to produce the products needed for our protocols and treatments," commented Zsolt Lisziewicz, COO of the Company.
Plasmids are closed circular molecules of double-stranded DNA that range in size from 1 to > 20 kB. Plasmids often contain genes that code for antigens and enzymes that can be advantageous to the host cell in some circumstances. The encoded proteins may be involved in inducing immune responses, resistance to, or production of antibiotics, resistance to toxins. Genetic Immunity proprietary DermaVir Patch technology uses special, 12kB plasmid-DNA, encoding most of the HIV genetic information. The plasmid is formulated to a nanomedicine and delivered to the dendritic cells of the lymph nodes to induce potent immune responses.
For more information please visit the Company's official website at http://www.geneticimmunity.com or contact Zsolt Lisziewicz directly at +36-1-272-0364
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Contact:
Contact:
At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
Created: 10/10/2008 5:09:02 PM Board type: Free
Power of the Dream Ventures Announces Equity Commitment of up to $5,000,000
BUDAPEST, HUNGARY, Oct 09, 2008 (MARKET WIRE via COMTEX) -- Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, today announced that it has finalized a financing commitment of up to $5,000,000 from a YA Global Investments, L.P. The terms of the financing allow the Company to sell up to $5,000,000 in tranches of equity, based upon a specified discount to the market price of the Company shares, calculated over the five trading days following notice of an election to sell shares.
This financing commitment provides the Company with the capital necessary to continue the development of the Company's current technology portfolio and to acquire additional technologies.
"This commitment allows us to finish executing our business plan and bring to market a number of significant technologies we have been incubating. I believe this coming year will bring significant progress for us, including the launch of our iGlue software and RiverPower technologies, among others," commented Viktor Rozsnyay, CEO of the Company. "This commitment shows trust in the company and our business model. Now it's our turn to fully execute and provide return to our investors from technology commercialization revenues," Mr. Rozsnyay added.
In connection with the financing commitment, YA Global also acquired a warrant to purchase up to an additional 4,027,386 shares of common stock.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, and co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com.
Options: Sign up for 'Power of the Dream Ventures, Inc. ' E-Mail List
Power of the Dream Ventures Announces Equity Commitment of up to $5,000,000
BUDAPEST, HUNGARY, Oct 09, 2008 (MARKET WIRE via COMTEX) -- Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, today announced that it has finalized a financing commitment of up to $5,000,000 from a YA Global Investments, L.P. The terms of the financing allow the Company to sell up to $5,000,000 in tranches of equity, based upon a specified discount to the market price of the Company shares, calculated over the five trading days following notice of an election to sell shares.
This financing commitment provides the Company with the capital necessary to continue the development of the Company's current technology portfolio and to acquire additional technologies.
"This commitment allows us to finish executing our business plan and bring to market a number of significant technologies we have been incubating. I believe this coming year will bring significant progress for us, including the launch of our iGlue software and RiverPower technologies, among others," commented Viktor Rozsnyay, CEO of the Company. "This commitment shows trust in the company and our business model. Now it's our turn to fully execute and provide return to our investors from technology commercialization revenues," Mr. Rozsnyay added.
In connection with the financing commitment, YA Global also acquired a warrant to purchase up to an additional 4,027,386 shares of common stock.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, and co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com.
Options: Sign up for 'Power of the Dream Ventures, Inc. ' E-Mail List
Mörderumsätze in US! 
Schönes WE
Schönes WE
Noch nen bißchen info Zeug gerade nichts zu tuen.
Website
http://www.powerofthedream.com/
http://river-power.com/
http://iglue.com/beta/
http://www.geneticimmunity.com/GI00.html
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website.
Hab mir mal 15k gegönnt, hop oder top
Website
http://www.powerofthedream.com/
http://river-power.com/
http://iglue.com/beta/
http://www.geneticimmunity.com/GI00.html
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website.
Hab mir mal 15k gegönnt, hop oder top
Trading Spotlight
Geht doch!!!
Genetic Immunity, InPlay: Company to Attend CLINAM European Conference for Clinical Nanomedicine
* Thursday April 23, 2009, 11:11 am EDT
*
Buzz up!
* Print
BUDAPEST, HUNGARY--(MARKET WIRE)--Apr 23, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Julianna Lisziewicz, Chief Executive Officer of the Company will be presenting at the European Conference for Clinical Nanomedicine, to be held from April 26-29, 2009 at the Basel Convention Center in Basel, Switzerland.
"The participants of this conference are working on nanotechnology-based drugs and biologics which have novel forms of therapeutic functionality meant to improve their efficacy and limit their negative side-effects. The interest in this clinical nanomedicine conference suggests that European entrepreneurs can be competitive globally and perhaps even spearhead the development of Nanomedicines. With our lead Nanomedicine Vaccine, the DermaVir Patch which is already in Phase II clinical trials, we are pioneering the field of Nanovaccines. Nanovaccines are just emerging as potential treatment and prevention solutions, and have recently gained recognition in the treatment of HIV, cancer and hepatitis. I look forward to exchange scientific and business information with other participants at the conference," commented Julianna Lisziewicz, CEO of the Company.
The European Conference for Clinical Nanomedicine is the annual scientific conference uniting clinicians and nanoscientists who have the common vision to apply nanoscience methods, tools and materials to the benefit of patients. It is a conference with European emphasis and international participation.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com.
Contact:
Contact:
At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
* Thursday April 23, 2009, 11:11 am EDT
*
Buzz up!
BUDAPEST, HUNGARY--(MARKET WIRE)--Apr 23, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Julianna Lisziewicz, Chief Executive Officer of the Company will be presenting at the European Conference for Clinical Nanomedicine, to be held from April 26-29, 2009 at the Basel Convention Center in Basel, Switzerland.
"The participants of this conference are working on nanotechnology-based drugs and biologics which have novel forms of therapeutic functionality meant to improve their efficacy and limit their negative side-effects. The interest in this clinical nanomedicine conference suggests that European entrepreneurs can be competitive globally and perhaps even spearhead the development of Nanomedicines. With our lead Nanomedicine Vaccine, the DermaVir Patch which is already in Phase II clinical trials, we are pioneering the field of Nanovaccines. Nanovaccines are just emerging as potential treatment and prevention solutions, and have recently gained recognition in the treatment of HIV, cancer and hepatitis. I look forward to exchange scientific and business information with other participants at the conference," commented Julianna Lisziewicz, CEO of the Company.
The European Conference for Clinical Nanomedicine is the annual scientific conference uniting clinicians and nanoscientists who have the common vision to apply nanoscience methods, tools and materials to the benefit of patients. It is a conference with European emphasis and international participation.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com.
Contact:
Contact:
At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
Immer son bißchen reicht ja!
Genetic Immunity, InPlay: Company to Present at the Bio International Convention in Atlanta
* On Wednesday May 13, 2009, 9:57 am EDT
*
Buzz up!
* Print
BUDAPEST, HUNGARY--(MARKET WIRE)--May 13, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Julianna Lisziewicz, Chief Executive Officer of the Company, will be presenting at the Bio International Convention, to be held from May 18-21, 2009 in Atlanta, Georgia.
Dr. Lisziewicz will discuss DermaPrep, Genetic Immunity's topical Dendritic Cell Targeting delivery system for pathogen-like vaccines. DermaPrep has been clinically tested in combination with the Company's unique vaccine nanoformulation technology that converts antigens (e.g. pDNA, proteins) into pathogen-like nanoparticles to mimic the natural danger signal of the body that results from pathogen exposure. The nanoparticle contains the antigen of the target disease complexed with a polymer to improve its stability and immunogenicity by protecting the antigen from degradation and ensuring the effective antigen presentation of Dendritic Cells. Dendritic Cells in turn generate long-term immunologic memory to protect against relapse. Several animal and human studies (Phase I and II) have demonstrated the safety, tolerability and immunogenicity of this approach.
"I am glad to be a presenter at the Bio International Convention. Our pipeline of products has reached a state of maturity that allows us to begin seeking industry partners for faster commercial introduction. This convention is the perfect venue to share our results and hopefully ink a number of partnership deals," commented Julianna Lisziewicz, CEO of the Company.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Contact:
Contact:
At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
* On Wednesday May 13, 2009, 9:57 am EDT
*
Buzz up!
BUDAPEST, HUNGARY--(MARKET WIRE)--May 13, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Julianna Lisziewicz, Chief Executive Officer of the Company, will be presenting at the Bio International Convention, to be held from May 18-21, 2009 in Atlanta, Georgia.
Dr. Lisziewicz will discuss DermaPrep, Genetic Immunity's topical Dendritic Cell Targeting delivery system for pathogen-like vaccines. DermaPrep has been clinically tested in combination with the Company's unique vaccine nanoformulation technology that converts antigens (e.g. pDNA, proteins) into pathogen-like nanoparticles to mimic the natural danger signal of the body that results from pathogen exposure. The nanoparticle contains the antigen of the target disease complexed with a polymer to improve its stability and immunogenicity by protecting the antigen from degradation and ensuring the effective antigen presentation of Dendritic Cells. Dendritic Cells in turn generate long-term immunologic memory to protect against relapse. Several animal and human studies (Phase I and II) have demonstrated the safety, tolerability and immunogenicity of this approach.
"I am glad to be a presenter at the Bio International Convention. Our pipeline of products has reached a state of maturity that allows us to begin seeking industry partners for faster commercial introduction. This convention is the perfect venue to share our results and hopefully ink a number of partnership deals," commented Julianna Lisziewicz, CEO of the Company.
About Genetic Immunity
Genetic Immunity is a US/Hungarian development stage biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Contact:
Contact:
At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate
* On Thursday June 11, 2009, 9:44 am EDT
*
Buzz up!
* Print
BUDAPEST, HUNGARY--(MARKET WIRE)--Jun 11, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in the Company's Phase II randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, immunogenicity, and antiretroviral activity of DermaVir Patch in treatment-naïve HIV-1-infected patients. The study is conducted in Hamburg, Germany with a total of thirty-six patients.
"We are very happy with completion of patient enrollment in this seminal trial because it allows us to conclude the immunization schedule in this year. This trial has a unique design to investigate DermaVir Patch as mono-immunotherapy in HIV-infected individuals who are not treated with antiretroviral drugs. We are very excited to learn how our immune therapeutic nanomedicine affects the immune system and disease of this patient population. With this trial we plan to demonstrate the safety and efficacy of DermaVir Patch as monotherapy administered every 6 weeks for the treatment of HIV," commented Julianna Lisziewicz, CEO of Genetic Immunity.
This novel plasmid DNA-based nanomedicine vaccine candidate, DermaVir Patch, has been under development in the last ten years. Phase I trial showed preliminary safety and tolerability and induction of memory T-cell immunity in all HIV-1-infected individuals. DermaVir is based on a single plasmid DNA capable to express most HIV antigens and to form a virus-like particle (VLP+). Plasmid DNA is formulated with a polymer to mimic a pathogen. DermaVir enters into the body via the Langerhans cells of the skin and induces memory immune responses in the lymph nodes.
The primary outcome of this phase II study measures safety and tolerability of DermaVir Patch, while secondary outcome includes HIV-1 RNA measurements to assess the antiretroviral activity of the DermaVir Patch, changes in CD4+, CD8+ T-cell counts and HIV-specific immunogenicity during DermaVir Patch treatment.
The study randomized patients into one of 6 arms: Arm 1 patients will receive low dose DermaVir patch (0.2 mg DNA, n=9); Arm 2 patients will receive low dose placebo patch (n=3); Arm 3 patients will receive medium dose DermaVir patch (0.4 mg DNA, n=9); Arm 4 patients will receive medium dose placebo patch (n=3); Arm 5 patients will receive high dose DermaVir patch (0.8 mg DNA, n=9); Arm 6 patients will receive high dose placebo patch (n=3).
Immunization will be done on days 0, 42, 84, and 126. The total number of patches that a patient will receive throughout the study will be 8, 16, or 32 in the low, medium, and high dose arms, respectively. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thighs. The same skin sites might be used for all patch immunizations that last for 3 hours.
Patients will be on-study for 282 weeks. The immunizations will be administered over an 18-week period with an identical follow up schedule continuing until week 24; patients will be followed for an additional 24 weeks for additional safety and immunogenicity evaluations. An additional 234 weeks safety follow-up will be performed including chemistry and hematology assessments and physical examinations.
For more information please visit the Company's official website at http://www.geneticimmunity.com
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
* On Thursday June 11, 2009, 9:44 am EDT
*
Buzz up!
BUDAPEST, HUNGARY--(MARKET WIRE)--Jun 11, 2009 -- Power of the Dream Ventures, Inc. (OTC BB:PWRV.OB - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in the Company's Phase II randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, immunogenicity, and antiretroviral activity of DermaVir Patch in treatment-naïve HIV-1-infected patients. The study is conducted in Hamburg, Germany with a total of thirty-six patients.
"We are very happy with completion of patient enrollment in this seminal trial because it allows us to conclude the immunization schedule in this year. This trial has a unique design to investigate DermaVir Patch as mono-immunotherapy in HIV-infected individuals who are not treated with antiretroviral drugs. We are very excited to learn how our immune therapeutic nanomedicine affects the immune system and disease of this patient population. With this trial we plan to demonstrate the safety and efficacy of DermaVir Patch as monotherapy administered every 6 weeks for the treatment of HIV," commented Julianna Lisziewicz, CEO of Genetic Immunity.
This novel plasmid DNA-based nanomedicine vaccine candidate, DermaVir Patch, has been under development in the last ten years. Phase I trial showed preliminary safety and tolerability and induction of memory T-cell immunity in all HIV-1-infected individuals. DermaVir is based on a single plasmid DNA capable to express most HIV antigens and to form a virus-like particle (VLP+). Plasmid DNA is formulated with a polymer to mimic a pathogen. DermaVir enters into the body via the Langerhans cells of the skin and induces memory immune responses in the lymph nodes.
The primary outcome of this phase II study measures safety and tolerability of DermaVir Patch, while secondary outcome includes HIV-1 RNA measurements to assess the antiretroviral activity of the DermaVir Patch, changes in CD4+, CD8+ T-cell counts and HIV-specific immunogenicity during DermaVir Patch treatment.
The study randomized patients into one of 6 arms: Arm 1 patients will receive low dose DermaVir patch (0.2 mg DNA, n=9); Arm 2 patients will receive low dose placebo patch (n=3); Arm 3 patients will receive medium dose DermaVir patch (0.4 mg DNA, n=9); Arm 4 patients will receive medium dose placebo patch (n=3); Arm 5 patients will receive high dose DermaVir patch (0.8 mg DNA, n=9); Arm 6 patients will receive high dose placebo patch (n=3).
Immunization will be done on days 0, 42, 84, and 126. The total number of patches that a patient will receive throughout the study will be 8, 16, or 32 in the low, medium, and high dose arms, respectively. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thighs. The same skin sites might be used for all patch immunizations that last for 3 hours.
Patients will be on-study for 282 weeks. The immunizations will be administered over an 18-week period with an identical follow up schedule continuing until week 24; patients will be followed for an additional 24 weeks for additional safety and immunogenicity evaluations. An additional 234 weeks safety follow-up will be performed including chemistry and hematology assessments and physical examinations.
For more information please visit the Company's official website at http://www.geneticimmunity.com
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Genetic Immunity, InPlay: Company to Present at Phacilitate's 8th Annual European Vaccine Forum
* Press Release
* Source: Power of the Dream Ventures, Inc.
* On Thursday June 18, 2009, 11:49 am EDT
*
Buzz up!
* Print
Power of the Dream Ventures, Inc. (OTC.BB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Dr. Julianna Lisziewicz, Chief Executive Officer of the Company, will be presenting "DermaVir Nanomedicine: The Next Generation DNA Vaccine" at Phacilitate's 8th annual European Vaccine Forum, to be held from June 22-24, 2009 Barcelona, Spain.
"I look forward to discussing the latest developments on our nanomedicine and dendritic cell targeting delivery system with conference attendees and to learn more about the progress of other companies active in the fields of immune therapy and vaccines. This event, just like the Bio International Convention in Atlanta, will give us many opportunities to look for partnerships and, or to reach for greater exposure of our immunotherapeutics technology," commented Julianna Lisziewicz, CEO of the Company.
Phacilitate is a specialist in the organization of exclusive events for leaders from the life sciences community. Their philosophy is simple -- to deliver the ultimate in strategic knowledge exchange and networking through flawless, personalized service. Phacilitate's 8th annual European Vaccine Forum will run in parallel this year to a new conference -- the Active Immunotherapeutics Forum. Dr. Lisziewicz will be attending both conferences.
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Contact:
Contact:
�At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
�At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
* Press Release
* Source: Power of the Dream Ventures, Inc.
* On Thursday June 18, 2009, 11:49 am EDT
*
Buzz up!
Power of the Dream Ventures, Inc. (OTC.BB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
Genetic Immunity is pleased to announce that Dr. Julianna Lisziewicz, Chief Executive Officer of the Company, will be presenting "DermaVir Nanomedicine: The Next Generation DNA Vaccine" at Phacilitate's 8th annual European Vaccine Forum, to be held from June 22-24, 2009 Barcelona, Spain.
"I look forward to discussing the latest developments on our nanomedicine and dendritic cell targeting delivery system with conference attendees and to learn more about the progress of other companies active in the fields of immune therapy and vaccines. This event, just like the Bio International Convention in Atlanta, will give us many opportunities to look for partnerships and, or to reach for greater exposure of our immunotherapeutics technology," commented Julianna Lisziewicz, CEO of the Company.
Phacilitate is a specialist in the organization of exclusive events for leaders from the life sciences community. Their philosophy is simple -- to deliver the ultimate in strategic knowledge exchange and networking through flawless, personalized service. Phacilitate's 8th annual European Vaccine Forum will run in parallel this year to a new conference -- the Active Immunotherapeutics Forum. Dr. Lisziewicz will be attending both conferences.
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the Company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. http://www.geneticimmunity.com
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
Contact:
Contact:
�At Genetic Immunity:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Phone: +36-1-272-0364
Fax: +36-1-272-0364
�At Power of the Dream Ventures:
Viktor Rozsnyay
President and CEO
Phone: +36-1-456-6061
Fax: +36-1-456-6062
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Italian Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine
* Press Release
* Source: Power of the Dream Ventures, Inc.
* On Wednesday July 1, 2009, 10:05 am EDT
*
Buzz up! 0
* Print
Power of the Dream Ventures, Inc. (OTC.BB:PWRV - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in the Company's Phase II randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). This second Phase II study is conducted at the IRCCS Policlinico S. Matteo in Pavia, Italy with a total of sixteen patients.
"We are extremely pleased to have enrolled all patients in this, our second Phase II trial aimed to prove the benefit of our immune amplification therapy. We now have two trials underway, in addition to a Phase I/II trial that is also nearing completion. I am confident this Italian trial, along with the one conducted in Hamburg, Germany will show substantial benefit for HIV infected patients. We look forward to receiving trial data once it is completed early in 2010," commented Julianna Lisziewicz, CEO of Genetic Immunity.
Subjects in the study are randomized to receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.
Patients are on study for a total of 29 weeks (nine weeks of HAART followed by 20 weeks of ATI). Each subject's DermaVir/Placebo application schedule is administered over an 8-week period (Day 0, 28, and 56). HAART is discontinued on Day 63 and is resumed on Day 203. Subsequently, individuals who do not meet HAART restarting criteria can elect not to restart therapy. After week 29 a safety and immunogenicity follow up evaluation is done every 3 months for an additional year for all the participants.
For more information please visit the Company's official website at http://www.geneticimmunity.com
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
* Press Release
* Source: Power of the Dream Ventures, Inc.
* On Wednesday July 1, 2009, 10:05 am EDT
*
Buzz up! 0
Power of the Dream Ventures, Inc. (OTC.BB:PWRV - News), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in the Company's Phase II randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). This second Phase II study is conducted at the IRCCS Policlinico S. Matteo in Pavia, Italy with a total of sixteen patients.
"We are extremely pleased to have enrolled all patients in this, our second Phase II trial aimed to prove the benefit of our immune amplification therapy. We now have two trials underway, in addition to a Phase I/II trial that is also nearing completion. I am confident this Italian trial, along with the one conducted in Hamburg, Germany will show substantial benefit for HIV infected patients. We look forward to receiving trial data once it is completed early in 2010," commented Julianna Lisziewicz, CEO of Genetic Immunity.
Subjects in the study are randomized to receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.
Patients are on study for a total of 29 weeks (nine weeks of HAART followed by 20 weeks of ATI). Each subject's DermaVir/Placebo application schedule is administered over an 8-week period (Day 0, 28, and 56). HAART is discontinued on Day 63 and is resumed on Day 203. Subsequently, individuals who do not meet HAART restarting criteria can elect not to restart therapy. After week 29 a safety and immunogenicity follow up evaluation is done every 3 months for an additional year for all the participants.
For more information please visit the Company's official website at http://www.geneticimmunity.com
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,02 | |
| +0,40 | |
| -2,56 | |
| -2,99 | |
| +2,94 | |
| +4,89 | |
| -0,95 | |
| +0,23 | |
| -0,90 | |
| +0,11 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 220 | ||
| 104 | ||
| 93 | ||
| 77 | ||
| 47 | ||
| 43 | ||
| 41 | ||
| 40 | ||
| 31 | ||
| 31 |
